Dova Pharmaceuticals Inc Avatrombopag ITP FDA Update Conference Call

27/6/2019 6:00

Conference Call Dova Pharmaceuticals Inc

Dova Pharmaceuticals Inc Conference call or earnings call will be held on Jun 27, 2019
During the earnings conference call’s session, Dova Pharmaceuticals Inc will provide updated information and financial performance report status.
In order to join the earning call, dial the conference’s bridge and key in the PIN code. Contact Dova Pharmaceuticals Inc for this information
More and more companies choose to conduct their earnings calls through conference calls and online meetings and it’s important to keep up to date with all relevant information.
Need a conference calls service solution? Try QCONF conferencing today, Sign up now and get 5 free conference calls (no credit card required)
Is this is your first earnings call? Check out Nasdaq guide for how to read an earnings report?
We are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Our drug candidate, avatrombopag, which we acquired from Eisai, Inc., or Eisai, in March 2016, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that we are developing for the treatment of thrombocytopenia. We have recently completed two identically designed pivotal Phase 3 clinical trials that evaluated avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease, or CLD, undergoing non-emergent minimally to moderately invasive medical procedures. Avatrombopag met the primary and secondary endpoints in each of these clinical trials with high statistical significance. Based on these results, a new drug application, or NDA, is planned for submission to the U.S.    
Read more Conference Call

Dova Pharmaceuticals Inc (DOVA)

2530 Meridian Parkway, Durham North Carolina 27713, United States